Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 22, 2024 1:30pm
82 Views
Post# 36001634

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals
  • To add valid context rather than speculation to Big Pharma's current merger and acquistion (M&A) activities  - Vertex Pharmaceuticals is acquiring Phase 1b Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven potential indications[ONCY has 2 registration ready clinical indications (mPDAC and mBC) and multiple additional indications (ie. anal cancer, TNBC, CRC, GI cancers, Gliomas, etc.)]
  • Povetacicept has shown results in reducing proteinuria in IgAN patients in their single phase 1b clinical trial.
  • The deal brings no revenues until at least 2027 and will produce modest upside for Vertex this decade.
<< Previous
Bullboard Posts
Next >>